VPD-737

DRUG2 trials

Sponsors

Vyne Therapeutics Inc., Jean Yuh Tang

Conditions

Chronic PruritusEpidermolysis BullosaPruritus

Phase 2

VPD-737 for Treatment of Chronic Pruritus

CompletedNCT01951274

Vyne Therapeutics Inc.Chronic Pruritus

Start: 2013-10-15End: 2014-12-02Updated: 2022-05-13

Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients

CompletedNCT02654483

Jean Yuh TangEpidermolysis Bullosa, Pruritus

Start: 2016-08-31End: 2018-07-27Updated: 2020-03-23

Related Papers

Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial.

2018-02-1776 citations